Literature DB >> 14607643

Diagnosis and treatment of insulinoma: report of 105 cases.

Liu-Shun Feng1, Xiu-Xian Ma, Zhe Tang, Yong-Fu Zhao, Xue-Xiang Ye, Pei-Qin Xu.   

Abstract

OBJECTIVE: To study the methods for diagnosis and treatment of insulinoma.
METHODS: Clinical data from 105 patients with insulinoma who had been admitted to our hospital from July 1966 to December 1999 were retrospectively reviewed.
RESULTS: Fasting blood glucose values were less than 2.75 mmol/L in all the patients. Fasting serum insulin values in 60 patients were higher than 25 mU/L, average 65 mU/L. Before operation, carcinoma was detected in 2 of 45 patients by ultrasound scan, and in 10 of 35 by CT. Enucleation of insulinoma was performed in 60 patients. Operations included insulinoma resection (35 patients), distal resection of the pancreas (8), and biopsy (2).
CONCLUSION: Whipple's triad and the index of insulin release >0.3 are the major variables for diagnosis. Intraoperative exploration and ultrasound scan are the methods for the localization of insulinoma. Enucleation of benign insulinoma is preferred, but proximal or distal resections of the pancreas are required only for large, deep or multiple tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14607643

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  3 in total

1.  Epidemiology of insulinoma in Tunisia.

Authors:  Melika Chihaoui; Rania Hmaissi; Mohamed Abid; Larbi Chaieb; Néjib Ben Abdallah; Abdeljelil Zaouche; Habib Houman; Lilia Rokbani; Hedia Slimane
Journal:  Endocrine       Date:  2011-10       Impact factor: 3.633

2.  The incidence of insulinoma in Western Sweden between 2002 and 2019.

Authors:  Ellinor Svensson; Andreas Muth; Per Hedenström; Oskar Ragnarsson
Journal:  Ann Gastroenterol       Date:  2022-03-25

Review 3.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.